Abstract
In this study, we investigated the regulation of different G protein-coupled receptor (GPCR)-stimulated signaling pathways by GPCR kinase 2 (GRK2). We used thyrotropin receptor, which is coupled to different G proteins, to investigate the regulation of Gαs- and Gαq-mediated signaling (assessed by cAMP and inositol phosphate production, respectively). In transfected cells, both pathways were desensitized by GRK2. However a kinase-dead GRK2 mutant (GRK2-K220R) only decreased inositol phosphate production, indicating that GRK2 could regulate Gαq signaling through a phosphorylation-independent mechanism. Similar results were obtained with serotonin receptor 5-hydroxytryptamine2C, which is coupled to Gαq. This effect was mimicked by the N-terminal domain of GRK2 (GRK2-Nter), but not by the C-terminal domain. In cells transfected with Gαq, direct activation of Gαq signaling (by AlF4 −) was desensitized by GRK2-Nter, indicating an effect at the Gα-level. For comparison, in parallel samples we studied a protein regulator of G protein signaling RGS4 and we found a similar regulatory profile. We therefore hypothesized that the GRK2-Nter could directly interact with the Gαq subunit to regulate its signaling, as demonstrated for several RGS proteins. This hypothesis is further supported by the presence, within the GRK2-Nter, of an RGS homology domain. In direct binding experiments, we found that GRK2-Nter interacts with Gαq (only when activated) but not with Gαs and Gαo. We conclude that GRK2, besides desensitizing the GPCR by phosphorylation, is able to selectively bind to Gαq and to regulate its signaling.
Footnotes
- Received October 21, 1999.
- Accepted January 3, 2000.
-
Send reprint requests to: Antonio De Blasi, Consorzio Mario Negri Sud, via Nazionale 66030 S. Maria Imbaro, Italy. E-mail:deblasi{at}cmns.mnegri.it
-
↵1 Recipient of a fellowship granted by Progetto Speciale Ricerca Scientifica e Applicata nel Mezzogiorno PS35–93/IND.
-
This study was supported by Telethon-Italy (Grant 1238), the Associazione Italiana per la Ricerca sul Cancro, Consiglio Nazionale delle Richerche Target Project on Biotechnology, and EC Biomed 2 program-PL 963566.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|